Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04617795 · ClinicalTrials.gov registry record · NA
Omnipod® 5 Automated Insulin Delivery System in Patients With Type 2 Diabetes
A NA study, sponsored by Insulet Corporation.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT04617795: Completed NA study, sponsored by Insulet Corporation.
NCT04617795 is a NA study that has completed, run by Insulet Corporation. The registered enrollment target is 25 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04617795, a NA study, has completed, sponsored by Insulet Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
The study subjects will be separated into 2 groups, depending on their previous insulin therapy with approximately 50% of subjects from each group, continuous glucose monitoring (CGM) naive. Group A will complete a 2-week Standard Therapy Phase followed by 8 weeks of Omnipod 5 system use. Group B will complete a 2-week Standard Therapy Phase followed by 10 weeks of Omnipod 5 system use. Group A and Group B will have an optional 6-month extension of Omnipod 5 system use
Primary Outcome
Overall percentage of time ≥250 mg/dL during standard therapy phase and ALL phases of Automated Mode
Interventions
- DEVICE Omnipod 5 Automated Insulin Delivery System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-11-23 |
| Est. Completion | 2022-03-06 |
| Phase | NA |
What the finished NCT04617795 record still lists
NCT04617795 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Omnipod 5 Automated Insulin Delivery System is the first listed.
NCT04617795 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04617795 about?
NCT04617795 is a clinical study titled "Omnipod® 5 Automated Insulin Delivery System in Patients With Type 2 Diabetes". The study subjects will be separated into 2 groups, depending on their previous insulin therapy with approximately 50% of subjects from each group, continuous glucose monitoring (CGM) naive. Group A will complete a 2-week Standard Therapy Phase followed by 8 weeks of Omnipod 5 system use. Group B ...
What is the current status of trial NCT04617795?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2020-11-23. Estimated completion is 2022-03-06.
What interventions are being tested in trial NCT04617795?
The interventions under investigation include: Omnipod 5 Automated Insulin Delivery System (DEVICE).
Who is sponsoring clinical trial NCT04617795?
This trial is sponsored by Insulet Corporation, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04617795's enrollment target sits among peer trials
25 1712th of 2000 higher than 265 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI